

1 Free cortisol and free 21-deoxycortisol in the clinical evaluation of congenital 2 adrenal hyperplasia

3 *Bas P.H. Adriaansen^{1,2*}, Agustini Utari³, André J. Olthaar¹, Rob C.B.M. van der Steen¹, Karijn J.*
4 *Pijnenburg-Kleizen⁴, Lizanne Berkenbosch^{2,5}, Paul N. Span⁶, Fred C.G.J. Sweep¹, Hedi L. Claahsen-van*
5 *der Grinten^{2†}, Antonius E. van Herwaarden^{1†}*

6 † These authors contributed equally to this work and share last authorship

7
8 ¹Radboud university medical center, Department of Laboratory Medicine, Nijmegen, the
9 Netherlands; ²Amalia Children's hospital, Radboud university medical center, Department of
10 Pediatrics, Division of Pediatric Endocrinology, Nijmegen, the Netherlands; ³Diponegoro University,
11 Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Semarang,
12 Indonesia; ⁴Canisius Wilhelmina hospital, Department of Pediatrics, Nijmegen, the Netherlands;
13 ⁵MosaKids Children's hospital, Maastricht University Medical Centre+, Department of Pediatrics,
14 Division of pediatric Endocrinology, Maastricht, the Netherlands; ⁶Radboud university medical center,
15 Department of Radiation Oncology, Nijmegen, the Netherlands

16
17 **Keywords:** ACTH, CAH, cortisol, free cortisol, 21-deoxycortisol, free 21-deoxycortisol

18 19 *Corresponding author

20 Bas P.H. Adriaansen
21 Radboud university medical Center
22 Department of Pediatrics
23 Geert Grooteplein Zuid 10 (huispost 804)
24 Postbus 9101, 6500HB
25 Nijmegen, Gelderland, the Netherlands
26 Tel: +31 (0)24 361 4430
27 E-mail address: Bas.Adriaansen@radboudumc.nl
28 ORCID: 0000-0003-1439-236X

29 30 Funding

31 This work was funded by International Fund Congenital Adrenal Hyperplasia (IFCAH).

32 33 Disclosures

34 The authors have nothing to disclose.

35 **Abstract**

36 Context: Some patients with classic congenital adrenal hyperplasia (CAH) survive without
37 glucocorticoid treatment. Increased precursor concentrations in these patients might lead to higher
38 free (biological active) cortisol concentrations by influencing the cortisol-protein binding. In 21-
39 hydroxylase deficiency (21OHD), the most common CAH form, accumulated 21-deoxycortisol (21DF),
40 a precursor steroid, may further increase glucocorticoid activity. Both mechanisms could explain the
41 low occurrence of symptoms in some untreated classic CAH patients.

42 Objective: Establishment and validation of an LC-MS/MS method for (free) cortisol and (free) 21DF to
43 quantify these steroids in untreated patients with classic CAH (n=29), non-classic CAH (NCCAH, n=5),
44 other forms of adrenal insufficiency (AI, n=3), and controls (n=11) before and 60 minutes after
45 Synacthen® administration.

46 Results: Unstimulated total cortisol levels of untreated classic CAH patients (median 109 nmol/L)
47 were lower compared to levels in untreated NCCAH patients (249 nmol/L, p=0.010) and controls (202
48 nmol/L, p=0.016), but free cortisol concentrations were similar. Basal free 21DF levels were high in
49 21OHD patients (median 5.32 nmol/L) and undetectable in AI patients and controls (<0.19 nmol/L).
50 After Synacthen® administration, free concentrations of 21DF -but not cortisol- increased only in
51 patients with 21OHD.

52 Conclusions: Free cortisol levels were similar in classic CAH compared to controls and NCCAH
53 patients, suggesting a comparable availability of cortisol. Additionally, 21OHD patients produce high
54 levels of the glucocorticoid 21DF, possibly explaining the low occurrence of symptoms in some classic
55 21OHD patients. Free cortisol and (free) 21DF levels should be considered in the clinical evaluation of
56 adrenal insufficiency in patients with CAH.

57

58 **Introduction**

59 Glucocorticoids, like cortisol, are among others essential for maintaining blood pressure, glucose
60 metabolism, and modulating the immune response [1, 2]. Cortisol is produced by the adrenal cortex
61 and has a diurnal rhythm with the highest concentration in the early morning [3]. The hypothalamus
62 regulates this rhythm by stimulating the pituitary gland, which subsequently produces
63 adrenocorticotrophic hormone (ACTH). Negative feedback by cortisol balances the activity of the
64 hypothalamus-pituitary-adrenal (HPA) axis. During periods of physical stress, such as infection or
65 surgery, the demand for cortisol increases, which is mediated by an increased ACTH release.

66 Patients with primary adrenal insufficiency (PAI) have insufficient cortisol production and are unable
67 to increase cortisol levels during periods of stress. This leads to symptoms of cortisol deficiency such
68 as extreme fatigue, weight loss, and abdominal pain. In adults, PAI is most often caused by acquired
69 conditions such as auto-immune adrenalitis, known as Addison's disease. In children, PAI is generally

70 caused by inherited conditions affecting adrenal steroid production. The most common inherited
71 form of PAI is classic congenital adrenal hyperplasia (CAH) caused by an enzyme deficiency in the
72 adrenal steroidogenesis pathway. Most CAH patients have 21-hydroxylase deficiency (21OHD) (90 –
73 95%) or 11-hydroxylase deficiency (11-OHD) (~5%). These patients have insufficient cortisol
74 production and consequently, a reduced negative feedback to the pituitary gland, causing chronically
75 elevated ACTH levels. This leads to continuous activation of the adrenal cortex and accumulation of
76 precursor steroids before the enzymatic block. These precursor steroids are partly shunted into the
77 unaffected adrenal androgen pathway, leading to hyperandrogenism. So, in contrast to other forms
78 of PAI, the hallmark of classic CAH is not only a decreased concentration of cortisol but also strongly
79 elevated concentrations of precursor steroids and adrenal androgens. Patients with non-classic CAH
80 (NCCAH), a less severe subgroup, generally produce normal concentrations of cortisol but still have
81 elevated concentrations of precursor steroids and androgens [4].

82 The first step in diagnosing PAI is measuring morning total cortisol concentrations in blood. To
83 evaluate the potential responsiveness of the HPA axis to stress, stimulation tests are performed, such
84 as the insulin tolerance test (ITT) [5] or the Synacthen® test [6]. In these tests, a suboptimal cortisol
85 response is defined as a total cortisol concentration <500 nmol/L (18 µg/dL) [7], but there is an
86 ongoing debate on this threshold [8]. In the CAH guideline, the cut-off is defined as <400 – 500
87 nmol/L (<14 – 18 µg/dL), depending on the measuring method [9].

88 Cortisol is in blood mostly bound to proteins (±95%), such as corticosteroid-binding globulin (CBG)
89 and albumin [10, 11]. The measured total cortisol is comprised of the bound and free (i.e., unbound)
90 cortisol, while, according to the free hormone hypothesis, only the latter determines the biological
91 glucocorticoid activity [12]. In addition, patients with 21OHD have elevated levels of 17-
92 hydroxyprogesterone (17OHP) that can be metabolized by 11-hydroxylase into 21-deoxycortisol
93 (21DF) [13]. Interestingly, previous studies have described untreated classic CAH patients with
94 insufficient cortisol production without overt complaints of cortisol deficiency [14-17]. Our group
95 showed that 21DF can transactivate the glucocorticoid receptor with a relative potency of 49%
96 compared to cortisol, the most potent endogenous glucocorticoid. Hence, 21DF contributes to the
97 glucocorticoid activity, especially when the concentration is significantly increased, such as in
98 patients with 21OHD [14]. In addition, it is known that precursor steroids can bind to CBG [11, 18,
99 19], thereby competing with cortisol for bindings spots on CBG and preventing cortisol from binding,
100 therewith increasing the free fraction of cortisol. These mechanisms might contribute to the
101 attenuation of symptoms in patients with untreated classic CAH. So far, no studies have been
102 conducted on free cortisol and free 21DF measurements in patients with CAH. Our aim is to quantify
103 total and free concentrations of cortisol and 21DF in the morning and 60 minutes after
104 administration of Synacthen® in patients with untreated classic CAH (both 11OHD and 21OHD). We

105 will compare these results with patients with NCCAH, patients with adrenal insufficiency (AI) but not
106 CAH, and controls to investigate the situation of CAH patients in more detail. We hypothesize that
107 free cortisol and (free) 21DF concentrations might give a better reflection of the glucocorticoid
108 activity in patients with 21OHD compared to solely measuring total cortisol levels.

109

110 **Materials and methods**

111 *Subjects*

112 This study was approved by the local medical ethics committee (Radboudumc, case number 2021-
113 12944). Patients were included via three routes (see Figure S1):

- 114 (I) Indonesian cohort (n=22): Serum samples from an Indonesian cohort of untreated classic
115 CAH patients (21OHD, n=17; 11OHD, n=5) were obtained as previously described [14].
116 Ethical approval was obtained from the ethical committee of the Faculty of Medicine,
117 Diponegoro University, Semarang, Indonesia (713/EC/FK-RSDK/2016).
- 118 (II) Dutch retrospective cohort (n=39): Stored residual serum samples from Synacthen® tests
119 performed between January 2016 and March 2021 were retrospectively collected.
- 120 (III) Dutch prospective cohort (n=19): Residual serum and plasma samples were obtained
121 from three hospitals in the Netherlands between April 2021 and January 2024.

122 For the Synacthen® tests, blood was obtained before (T_0) and 60 minutes after (T_{60}) administration of
123 250 µg Tetracosactide. Samples were kept frozen at ≤ -30 °C until analysis. Inclusion criteria were:
124 ≥ 300 µL residual serum available and patients not treated with systemic glucocorticoids for at least
125 one year before blood withdrawal. Pseudonymized data about age, gender, time of blood
126 withdrawal, indication of Synacthen® test, and diagnosis were collected. Patients were divided into
127 four groups: (I) patients with classic CAH (both 21OHD and 11OHD), (II) patients with NCCAH based
128 on 21OHD, (III) patients with adrenal insufficiency (AI) but not CAH, and (IV) patients with an optimal
129 cortisol response after Synacthen® (controls). Classification of CAH patients in classic CAH and NCCAH
130 was based on clinical characteristics, biochemical evaluation, and genetic analysis (Table S1) [20, 21].
131 Sequencing results were compared to the reference sequence GenBank NM_000500.9 for *CYP21A2*
132 and NM_000497.3 for *CYP11B1*. In this article the term ‘classic CAH’ refers to both 21OHD and
133 11OHD patients.

134

135 *Measurement of total steroid concentrations with LC-MS/MS*

136 Total serum 17OHP (17-hydroxypreg-4-ene-3,20-dione), 11-deoxycortisol (17,21-dihydroxypreg-4-
137 ene-3,20-dione), 21DF (11,17-dihydroxypreg-4-ene-3,20-dione), and cortisol (11,17,21-
138 trihydroxypreg-4-ene-3,20-dione) were analyzed by a clinically validated liquid chromatography
139 tandem mass spectrometry (LC-MS/MS) method on a 6490 triple quadrupole LC-MS/MS (Agilent

140 Technologies, Santa Clara, CA) preceded by protein precipitation and solid phase extraction (SPE). An
141 internal standard mix (20 μL in methanol:H₂O 30:70) containing [¹³C₃]-17OHP, [²H₅]-11-deoxycortisol,
142 [²H₄]-21DF, and [¹³C₃]-cortisol (all from Isosciences, Ambler, PA) with concentrations of 10, 10, 20,
143 and 100 nmol/L, respectively, was added to 100 μL serum. For protein precipitation, acetonitrile +
144 0.1% formic acid was added and incubated for at least 10 minutes at room temperature and
145 centrifuged (10 min, 5000g). Then, 200 μL supernatant was added to 300 μL H₂O followed by SPE
146 using Oasis® HLB 1cc cartridges (Waters Corporation, Milford, MA). These cartridges were
147 preequilibrated with 1 mL methanol:isopropanol (95:5) and consequently washed with 1 mL H₂O.
148 After sample application, columns were washed with 1 mL H₂O and 1 mL methanol:H₂O (30:70). The
149 eluate (300 μL , methanol:isopropanol 95:5) was dried under a stream of N₂ gas at 40 °C,
150 reconstituted in 100 μL methanol:H₂O (30:70) and injected (10 μL) into an Agilent Technologies 1290
151 Infinity UHPLC-system (Agilent Technologies). LC-MS/MS settings are shown in Table S2. The collision
152 energy was optimized for each analyte and internal standard and two mass transitions (quantitative
153 and qualitative) were monitored. A nine-point calibration curve with 17OHP, 11DF, 21DF, and cortisol
154 (all from Sigma-Aldrich, St. Louis, MO, USA) was used for quantification. The calibration ranges were
155 0 – 167 nmol/L for 17OHP, 0 – 191 nmol/L for 11DF, 0 – 167 nmol/L for 21DF, and 0 – 2,299 nmol/L
156 for cortisol. In-house quality controls of human serum were measured in duplicate in each run.

157

158 *Measurement of free steroid concentrations with LC-MS/MS*

159 Measurement of free 21DF was incorporated in a clinically validated measuring method for free
160 cortisol and free testosterone. Equilibrium dialysis was performed with samples buffered to pH 7.4 (\pm
161 0.03) at 37 °C (\pm 0.5) by a previously described HEPES buffer (4-(2-Hydroxyethyl)piperazine-1-
162 ethanesulfonic acid; Merck, Rahway, NJ, USA) that resembled the ionic environment of serum [22].
163 Two identical volume compartments (180 μL) were separated by a semipermeable regenerated
164 cellulose membrane (Serva Electrophoresis GmbH, Heidelberg, Germany) with a diameter of 28 mm
165 and maximum permeability of 5 kDA. During dialysis, cells were placed in a water bath at 37 °C (\pm 0.5)
166 for 5h while continuously rotating. After dialysis, dialysate was emptied from the cell and SPE was
167 performed with 100 μL preceded by the addition of H₂O (30 μL) and an internal standard mix (20 μL)
168 containing [²H₄]-21DF, [¹³C₃]-cortisol, and [¹³C₃]-testosterone (all from IsoSciences). For SPE, Oasis®
169 MCX 1cc cartridges (Waters Corporation) were preequilibrated with 1 mL methanol:isopropanol
170 (95:5) and consequently washed with 1 mL H₂O. After sample application, columns were washed with
171 1 mL H₂O + 5% ammonium hydroxide and 1 mL methanol:H₂O (20:80) + 2% formic acid. The eluate
172 (300 μL , 100% methanol) was dried in the Savant™ SpeedVac™ Concentrator (ThermoFisher
173 Scientific, Waltham, MA, USA) for \pm 1h, reconstituted in 30 μL methanol:H₂O (30:70) and injected (10
174 μL) into a Xavi® TQ-XS StepWave XS™ triple quadrupole spectrometer (Waters Incorporation). LC-

175 MS/MS settings including collision energy and mass transitions are shown in Table S3. A nine-point
176 calibration curve with 21DB (Steraloids, Newport, RI, USA), 21DF, and cortisol (both from Sigma-
177 Aldrich) was used for quantification. The calibration ranges were 0 – 115 nmol/L for all three
178 steroids.

179

180 *Method validation*

181 All measurements were performed in an ISO15189 accredited laboratory. All clinically validated
182 measuring methods are monitored for quality in each run using in duplicate measurements of in-
183 house quality controls of human serum. For validation, a CLSI EP6 protocol [23] in serum was used to
184 assess linearity. We measured steroid concentrations in a blank sample that was injected after the
185 highest standard to assess carry-over. Ion suppression was measured according to CLSI C62-A
186 guideline [24]: qualitative ion suppression by continuous infusion of the labeled steroid, and
187 quantitative ion suppression by comparing the signal of human serum measurements (n=5) with the
188 signal of spiked prepared matrix-free blank. Imprecision was assessed by a modified CLSI EP5
189 protocol [25] with pooled human serum samples at a low (n=7 for 21DF; n=20 for cortisol) and high
190 concentration (n=8 for 21DF, n=20 for cortisol). The lower limit of quantification (LLOQ) was defined
191 as the lowest concentration with an inter-assay coefficient of variation (CV) <20% and was
192 determined with a modified EP evaluator protocol from pooled serum by between-day assay
193 repeated measurements (n=10). For 21DF, recovery was calculated in five samples to which 29.94
194 nmol/L was added. For cortisol, a National Institute of Standards and Technology (NIST) standard
195 (LOT number: 271020) diluted to 1.496 nmol/L was measured each run (n=29). A correction factor of
196 1.03 was applied to adjust free cortisol levels according to the NIST standard. Possible interfering
197 substances were identified by measuring commercially available steroids and anti-androgens with a
198 molecular mass ≤ 2 g/mol lower than the analyte or the internal standard. First, retention time
199 interference was checked, and second, MRM transition interference was evaluated.

200

201 *Data and statistical analyses*

202 Free cortisol percentage was calculated by dividing the free cortisol concentration by the total
203 cortisol concentration from the same sample multiplied by 100%. Since cortisol has a diurnal rhythm,
204 only morning samples (between 08.00 – 11.00 AM) were used for the analyses of absolute free and
205 total cortisol concentrations. Results <LLOQ with a signal-to-noise ratio <5 were assigned a value of
206 half the LLOQ. These results were excluded from the calculation of percentages. A Kruskal-Wallis test
207 was used to compare means between different subgroups (classic CAH vs NCCAH vs AI vs control).
208 For comparison of related samples (T_0 vs T_{60}), a related-samples Wilcoxon signed ranked test was
209 used.

210

211 **Results**

212 *Subjects*

213 In total, data from 22 Indonesian and 58 Dutch patients were collected, see Figure S1 for the
214 inclusion flowchart. Patients with an insufficient volume of residual material (n=31) and patients
215 treated with glucocorticoids before the test were excluded (n=1). In total, 48 patients were divided
216 into four groups: classic CAH (n=29; 21OHD [n=24] and 11OHD [n=5]), NCCAH (n=5), AI (n=3), and
217 controls (n=11). Demographics of included patients are shown in Table 1.

218

219 *Method validation*

220 An LC-MS/MS method for free cortisol and free 21DF was established and validated. The
221 measurement of 21DF was linear between 0.13 and 99.2 nmol/L and the measurement of free
222 cortisol was linear between 0.08 and 66 nmol/L. The maximum deviation from linearity, imprecision,
223 LLOQ, recovery, and ion suppression are shown in Table 2. Carry-over was negligible for both
224 components. For cortisol and its internal standard, we evaluated 18-hydroxycorticosterone as
225 possible interfering substance and it showed no interference. For 21DF and its internal standard,
226 corticosterone, 11-deoxycortisol, and 18-hydroxy-11-deoxycorticosterone were evaluated and
227 showed no interference.

228

229 *Baseline*

230 *Morning free cortisol levels in classic CAH patients are similar to levels in controls at T₀*

231 The median total cortisol concentration in the morning (samples at T₀) was 106 nmol/L in the
232 untreated classic CAH patients, which was significantly lower than NCCAH patients (249 nmol/L,
233 p=0.010) and controls (202 nmol/L, p=0.016) (Figure 1A).

234 Interestingly, the median *free* morning cortisol concentration in untreated classic CAH patients (8.62
235 nmol/L) was not significantly different from NCCAH patients (9.84 nmol/L, p=0.313) and controls
236 (6.94 nmol/L, p=0.573) (Figure 1B). So, in contrary to the total cortisol concentrations, this suggests a
237 comparable availability of cortisol in our classic CAH cohort compared to NCCAH patients and
238 controls.

239 In untreated classic CAH patients, the concentration of free cortisol is higher than expected based on
240 the total cortisol concentration. This is also indicated by the percentage of free cortisol, which was
241 7.5% for classic CAH patients, significantly higher than free cortisol percentages of NCCAH patients
242 (5.5%, p=0.025), AI patients (2.1%, p<0.001), and controls (3.3%, p<0.001) (Figure S2A).

243

244 *Patients with 21OHD have increased total 21DF concentrations compared to AI patients and controls*

245 Patients with 21OHD have increased total 21DF concentrations with a median of 67.5 nmol/L at T₀.
246 This was significantly higher compared to all other groups: NCCAH patients had a median of 3.03
247 nmol/L (p=0.020), and total 21DF concentrations in AI patients and controls were all <LLOQ (0.7
248 nmol/L) (p<0.001) (Figure 1C).

249 For *free* 21DF concentrations at T₀, the same is observed: the median concentration in 21OHD
250 patients (5.32 nmol/L) was significantly higher compared to median levels in NCCAH patients (0.34
251 nmol/L; p=0.025), AI patients (<0.19 nmol/L, (p=0.003), and controls (<0.19 nmol/L, p<0.001) (Figure
252 1D).

253

254 In all 11OHD patients, total and free 21DF concentrations were <LLOQ (data not shown).

255

256 After Synacthen® stimulation

257 *Patients with classic CAH have lower (free) cortisol concentrations T₆₀ compared to controls*

258 All controls had a total cortisol concentration ≥500 nmol/L at T₆₀ (median 658 nmol/L), indicating
259 sufficient cortisol production during stress according to current guidelines [7]. In NCCAH patients,
260 total cortisol concentrations increased with a median of 42% (p=0.043), although not with the same
261 steep increase as observed in controls (198%; p=0.005). In none of the NCCAH patients the 500
262 nmol/L threshold (median 402 nmol/L) was reached, but 60% (3/5) of them reached the 400 nmol/L
263 threshold as proposed in the CAH guideline [9]. In the remaining two NCCAH patients, stimulated
264 total cortisol concentrations of 305 and 397 nmol/L were measured. Total cortisol concentrations did
265 not increase upon Synacthen® administration in classic CAH and AI patients (p=0.466 and p=0.655,
266 respectively) (Figure 2A). Classic CAH (median 119 nmol/L) and AI patients (median 172 nmol/L) did
267 both not reach the 500 nmol/L threshold [7] nor the 400 nmol/L threshold [9], indicating adrenal
268 insufficiency, as expected in these patients.

269 The *free* cortisol concentration increased after Synacthen® administration in classic CAH patients by
270 10.7% (p=0.001). In NCCAH patients and controls, we observed a median increase of 144% (p=0.043)
271 and 610% (p=0.005), respectively. No significant increase in the free cortisol concentration was
272 observed in AI patients (p=0.655) (Figure 2B). At T₆₀, the median *free* cortisol concentration in classic
273 CAH patients was 9.85 nmol/L, which was significantly lower compared to levels in NCCAH patients
274 (33.8 nmol/L, p=0.010) and controls (63.6 nmol/L, p<0.001), but not significantly different from AI
275 patients (5.08 nmol/L, p=0.377) (data not shown). In all controls, an increase of free cortisol ≥37
276 nmol/L after stimulation was measured. Levels of free cortisol after Synacthen® stimulation in
277 NCCAH patients ranged from 22 to 45 nmol/L. Patients with classic CAH did not reach serum levels of
278 free cortisol seen in controls after Synacthen® (maximum 21.8 nmol/L).

279 After Synacthen®, the *percentage of free cortisol* increased in classic CAH ($p=0.001$), NCCAH
280 ($p=0.043$), and control patients ($p=0.005$), but not in AI patients ($p=0.655$) (Figure S2B). At T_{60} , the
281 median free cortisol percentage of classic CAH patients (8.9%) was significantly higher compared to
282 AI patients (2.9%, $p=0.019$) but not significantly different from NCCAH patients (7.4%, $p=0.235$) and
283 controls (9.7%, $p=0.520$) (Figure S2C).

284

285 *Concentrations of free 21DF increase after Synacthen® administration in classic 21OHD patients*

286 The total 21DF concentration significantly increased upon ACTH stimulation in NCCAH patients
287 ($p=0.043$), but not in classic 21OHD patients ($p=0.121$) (Figure 2C). At T_{60} , the median total 21DF
288 concentrations in classic 21OHD and NCCAH patients were 94.6 nmol/L and 26.4 nmol/L,
289 respectively. The total 21DF concentration in AI patients remained <LLOQ at T_{60} . In controls, the
290 maximum total 21DF concentration was twice the LLOQ (0.7 nmol/L) for two patients. The 21OHD
291 patients had significantly higher total 21DF concentrations at T_{60} compared to AI patients ($p=0.005$)
292 and controls ($p<0.001$) (data not shown).

293 The free 21DF concentration significantly increased in both classic CAH ($p=0.023$) and NCCAH
294 patients ($p=0.043$) (Figure 2D). At T_{60} , the median free 21DF concentration was 7.34 nmol/L in classic
295 CAH patients and 2.22 nmol/L in NCCAH patients ($p=0.054$). For all AI patients, the free 21DF
296 concentration was <LLOQ at T_{60} . Controls had a median of 0.18 nmol/L free 21DF at T_{60} (data not
297 shown). In all 11OHD patients, total and free 21DF concentrations were <LLOQ (data not shown).

298 In classic 21OHD patients, the percentage of free 21DF was 8.4% at T_0 which significantly increased to
299 10.3% ($p=0.035$) at T_{60} . For NCCAH patients, there was no significant increase in the percentage of
300 free 21DF after ACTH stimulation, it was 8.8% both at T_0 and T_{60} (data not shown).

301

302 Discussion

303 In this study, we evaluated for the first time the concentrations of free cortisol and free 21DF in a
304 group of untreated patients with classic CAH (both 21OHD and 11OHD), NCCAH, other forms of AI,
305 and controls. We found that the *free* cortisol concentration in untreated classic CAH patients is
306 similar to the concentration in controls in the unstimulated situation, despite decreased *total* cortisol
307 levels. This could explain why some patients with classic 21OHD or 11OHD show no or only mild
308 symptoms of cortisol deficiency in the basal situation. In addition, patients with classic 21OHD have
309 elevated concentrations of total and free 21DF, which is not observed in AI patients and controls,
310 increasing the glucocorticoid activity. After Synacthen®, classic CAH patients show no increase in
311 their total cortisol levels and only a minimal increase in free cortisol levels, but we measured
312 increased free levels of the glucocorticoid 21DF in 21OHD patients. This might explain why these
313 patients survived periods of severe stress without glucocorticoid treatment.

314 For this study, we have developed an LC-MS/MS method to measure free cortisol and free 21DF. The
315 mean free cortisol percentage in our control group (3.7%) was similar to the percentage found by
316 others (3.95%) [26, 27]. We observed that the relative increase in free cortisol concentration (610%)
317 after Synacthen® administration was higher compared to the relative increase in total cortisol
318 (198%), which was also observed in other studies [26-28]. Therefore, evaluating free concentrations
319 may be more informative than evaluating total concentrations.

320 Glucocorticoids exert a plethora of functions in the human body, and they are especially necessary
321 during periods of stress. Therefore, two situations should be distinguished when interpreting
322 glucocorticoid levels: the daily baseline situation and an episode with physical stress.

323

324 *Baseline situation*

325 Cortisol in blood is mostly bound to CBG and albumin, but only its free form is biologically active
326 according to the free hormone hypothesis [29]. We found that in the baseline situation, *total* cortisol
327 concentrations of untreated classic CAH patients are lower compared to controls, but *free* cortisol
328 concentrations were similar. This is supported by data from Waaijers *et al.*, that found cortisol
329 concentrations within the reference range in hair of untreated classic CAH patients [30], suggesting
330 similar long-term free cortisol levels between classic CAH patients and the reference population. This
331 might be explained by several hypotheses: (I) In classic CAH patients, increased levels of structurally
332 analogous steroids, such as 17OHP and 21DF, may disrupt or prevent cortisol from binding to CBG or
333 albumin [11, 18, 19], leading to a higher percentage of free cortisol; (II) CAH patients have increased
334 concentrations of adrenal androgens, which are known to decrease 11 β -hydroxy steroid
335 dehydrogenase type 2 activity, preventing the conversion of active cortisol into inactive cortisone
336 [31]; (III) androgens are able to decrease CBG levels, thereby possibly increasing the free cortisol
337 concentrations [32, 33].

338 In addition, we found that in the basal situation, classic 21OHD patients have increased 21DF
339 concentrations, which confirms the findings of previous studies [34-36]. Our group showed that 21DF
340 has a relative potency of 49% to activate the glucocorticoid receptor compared to cortisol [14]. The
341 median free 21DF concentration in untreated classic CAH patients of 5.32 nmol/L would be
342 equivalent to $(0.49 \times 5.32 =) 2.61$ nmol/L cortisol. Hypothetically this adds to the glucocorticoid
343 activity of classic 21OHD patients. So, these patients have more glucocorticoid activity than expected
344 based on their total cortisol levels. This could explain why some classic CAH patients have lived
345 without glucocorticoid medication during daily circumstances. Patients with 11OHD are not capable
346 of producing 21DF, but their free cortisol levels were already similar to controls.

347

348 *During periods of stress*

349 During periods of physical stress, such as illness or surgery, there is a higher demand for
350 glucocorticoids. Classic CAH patients were not able to increase their total cortisol levels after ACTH
351 stimulation. In our study untreated classic CAH patients did not reach the 400-500 nmol/L total
352 cortisol threshold after Synacthen® administration [9]. We found only a small increase in free cortisol
353 levels, but classic CAH patients did not reach the increase in free cortisol levels of the control group.
354 Interestingly, we did observe an increase in the free concentration of the glucocorticoid 21DF in
355 patients with 21OHD up to a median of 7.34 nmol/L. Given that 21DF is capable of activating the
356 glucocorticoid receptor these increased concentrations may contribute significantly to the
357 glucocorticoid activity. However, it is questionable if this concentration of free glucocorticoids is
358 enough to reach sufficient glucocorticoid activity in these patients during periods of stress to prevent
359 Addisonian crisis. Therefore, it is still not entirely clear how previously described untreated classic
360 21OHD patients have survived periods of physical stress, such as dengue fever and surgery, without
361 glucocorticoid treatment [14-17]. Other protective measures might be important in these patients
362 during stress episodes. Kroon *et al.* have reviewed that androgens can also contribute to the
363 glucocorticoid activity either by direct binding to the glucocorticoid responsive elements or by
364 assisted loading [31], in which androgen signal transduction opens the chromatin, enabling activated
365 glucocorticoid receptors to bind the responsive elements and enhance glucocorticoid signaling. In
366 addition, Hamrahian *et al.* showed that the percentage of free cortisol increases in healthy
367 individuals after administration of synthetic ACTH [29]. The continuous ACTH pressure in classic CAH
368 patients might also directly increase the free cortisol percentage, leading to more free cortisol and
369 hence more glucocorticoid activity. It would be interesting to further investigate these hypotheses in
370 the specific situations of patients with CAH.

371

372 *Indication for glucocorticoid treatment*

373 Previously, we and others described classic CAH patients who have survived without glucocorticoid
374 treatment despite low total cortisol levels and the inability to increase total cortisol levels during
375 stress [14-17]. The similar concentration of free cortisol in untreated classic CAH patients compared
376 to controls might explain this clinical observation. Intriguingly, in clinical practice, some classic CAH
377 patients -mostly males and 46,XX individuals living as males- exhibit so few overt signs of adrenal
378 cortex insufficiency that they refuse glucocorticoid medication [37, 38]. However, patients have to be
379 counseled about the potential risks of being untreated; Besides the risk to develop an Addisonian
380 crisis, elevated ACTH levels can lead to the development of testicular adrenal rest tumors and
381 adrenal myelolipomas [37]. Furthermore, elevated levels of androgens and precursor steroids may
382 contribute to an unfavorable cardiovascular risk profile [39].

383 Genotype-phenotype correlations in CAH are not always accurate. In our study, we also found a
384 discrepancy between the expected phenotype based on genetics and the clinical phenotype,
385 especially for the R356W mutation in the *CYP21A2* gene. Stoupa *et al.* [40] reported that 60% of their
386 NCCAH patients had an inadequate cortisol response after Synacthen®, while none of them
387 experienced periods of cortisol deficiency, highlighting that not all patients with an insufficient total
388 cortisol concentrations have clinically relevant adrenal cortex insufficiency.

389

390 Our findings suggest that measuring total cortisol levels alone may not be the most appropriate way
391 to assess adrenal cortex function in all forms of PAI. Supplementary measurement of free cortisol
392 may provide a more accurate reflection of glucocorticoid activity. In 21OHD patients, the
393 concentration of (free) 21DF should also be considered to comprehensively evaluate the
394 glucocorticoid activity. This would be especially useful in patients with milder forms of CAH, to
395 indicate the necessity of glucocorticoid treatment. More research is necessary to compute cut-off
396 values for defining adrenal cortex insufficiency and to incorporate it in clinical practice.

397 Measuring free cortisol levels is not only useful for CAH patients, but also for patients with other
398 conditions in which there is a discrepancy between free and total cortisol levels, for instance patients
399 with hypoproteinemia during critical illness [29], patients with CBG-deficiency [10], or patients who
400 use oral contraceptive medication [41].

401

402 Our study has several strengths and limitations. This is the first study that quantified free cortisol and
403 free 21DF concentrations in untreated classic CAH patients. We did not only compare levels with
404 controls but also with patients with NCCAH and AI. Another strength is the use of a state-of-the-art
405 dialysis method to obtain free concentrations followed by a sensitive LC-MS/MS method, which is the
406 gold standard for steroid measurements in serum [9]. Furthermore, deuterium or ¹³C-isotopes of
407 each steroid were used as internal standards to allow for the correction of matrix effects. Moreover,
408 all included CAH patients were genetically confirmed. A limitation of our study is the small sample
409 size of the study groups, especially AI patients. PAI is rare and the volume of residual serum was not
410 always sufficient to perform the measurements. Cortisol has a diurnal rhythm, but not all samples
411 were taken in the morning. To correct for this, we only included measurements before 11.00 am in
412 the analyses for total and free cortisol.

413

414 To conclude, untreated classic CAH patients have free cortisol concentrations in the same range as
415 controls under basal conditions. Moreover, patients with 21OHD have an increased production of
416 total and free 21DF, a precursor steroid with glucocorticoid activity. Both mechanisms might explain
417 the low occurrence or lack of symptoms of adrenal insufficiency in daily situations in some untreated

418 classic CAH patients. During periods of stress, (free) 21DF concentrations increase in 21OHD patients,
419 in contrast to patients with other forms of PAI, with probably additional protective effects. Future
420 research should focus on the role of free cortisol and free precursor steroids, especially in milder
421 forms of CAH to accurately assess the glucocorticoid activity and indicate the necessity of
422 glucocorticoid treatment.

423

424 References

- 425 1. Whitworth, J.A., D. Saines, and B.A. Scoggins, *Blood pressure and metabolic effects of cortisol*
426 *and deoxycorticosterone in man*. Clin Exp Hypertens A, 1984. **6**(4): p. 795-809.
- 427 2. Cain, D.W. and J.A. Cidlowski, *Immune regulation by glucocorticoids*. Nat Rev Immunol, 2017.
428 **17**(4): p. 233-247.
- 429 3. Elverson, C.A. and M.E. Wilson, *Cortisol: Circadian Rhythm and Response to a Stressor*.
430 Newborn and Infant Nursing Reviews, 2005. **5**(4): p. 159-169.
- 431 4. Adriaansen, B.P.H., et al., *Challenges in treatment of patients with non-classic congenital*
432 *adrenal hyperplasia*. Front Endocrinol (Lausanne), 2022. **13**: p. 1064024.
- 433 5. Fraser, R., F. Albright, and P.H. Smith, *The Value of the Glucose Tolerance Test, the Insulin*
434 *Tolerance Test, and the Glucoseinsulin Tolerance Test in the Diagnosis of Endocrinologic*
435 *Disorders of Glucose Metabolism*¹. The Journal of Clinical Endocrinology & Metabolism, 1941.
436 **1**(4): p. 297-306.
- 437 6. Thorn, G.W., P.H. Forsham, and et al., *The use of adrenocorticotropin as a test of adrenal*
438 *cortical reserve*. J Clin Endocrinol Metab, 1948. **8**(7): p. 589.
- 439 7. Bornstein, S.R., et al., *Diagnosis and Treatment of Primary Adrenal Insufficiency: An*
440 *Endocrine Society Clinical Practice Guideline*. J Clin Endocrinol Metab, 2016. **101**(2): p. 364-
441 89.
- 442 8. Reynolds, R.M., et al., *Assessing the HPA axis in patients with pituitary disease: a UK survey*.
443 Clin Endocrinol (Oxf), 2006. **64**(1): p. 82-5.
- 444 9. Speiser, P.W., et al., *Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase*
445 *Deficiency: An Endocrine Society Clinical Practice Guideline*. J Clin Endocrinol Metab, 2018.
446 **103**(11): p. 4043-4088.
- 447 10. Lewis, J.G., et al., *Plasma free cortisol fraction reflects levels of functioning corticosteroid-*
448 *binding globulin*. Clin Chim Acta, 2005. **359**(1-2): p. 189-94.
- 449 11. Meyer, E.J., et al., *Pyrexia and acidosis act independently of neutrophil elastase reactive*
450 *center loop cleavage to effect cortisol release from corticosteroid-binding globulin*. Protein
451 Sci, 2020. **29**(12): p. 2495-2509.
- 452 12. Mendel, C.M., *The free hormone hypothesis: a physiologically based mathematical model*.
453 Endocr Rev, 1989. **10**(3): p. 232-74.
- 454 13. Claahsen-van der Grinten, H.L., et al., *Congenital Adrenal Hyperplasia-Current Insights in*
455 *Pathophysiology, Diagnostics, and Management*. Endocr Rev, 2022. **43**(1): p. 91-159.
- 456 14. Engels, M., et al., *Glucocorticoid Activity of Adrenal Steroid Precursors in Untreated Patients*
457 *With Congenital Adrenal Hyperplasia*. J Clin Endocrinol Metab, 2019. **104**(11): p. 5065-5072.
- 458 15. Speiser, P.W., et al., *Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia*
459 *with complete absence of adrenal 21-hydroxylase*. N Engl J Med, 1991. **324**(3): p. 145-9.
- 460 16. Utari, A., et al., *Challenges in the treatment of late-identified untreated congenital adrenal*
461 *hyperplasia due to CYP11B1 deficiency: Lessons from a developing country*. Front Endocrinol
462 (Lausanne), 2022. **13**: p. 1015973.
- 463 17. Aveiro-Lavrador, M., et al., *Late diagnosis of classic congenital adrenal hyperplasia: long-term*
464 *consequences during adulthood*. Endocrinol Diabetes Metab Case Rep, 2021. **2021**.

- 465 18. de Moor, P., R. Deckx, and O. Steeno, *Influence of various steroids on the specific binding of*
466 *cortisol*. *J Endocrinol*, 1963. **27**: p. 355-6.
- 467 19. Dunn, J.F., B.C. Nisula, and D. Rodbard, *Transport of steroid hormones: binding of 21*
468 *endogenous steroids to both testosterone-binding globulin and corticosteroid-binding*
469 *globulin in human plasma*. *J Clin Endocrinol Metab*, 1981. **53**(1): p. 58-68.
- 470 20. Baumgartner-Parzer, S., M. Witsch-Baumgartner, and W. Hoepfner, *EMQN best practice*
471 *guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency*. *Eur J Hum*
472 *Genet*, 2020. **28**(10): p. 1341-1367.
- 473 21. Krone, N. and W. Arlt, *Genetics of congenital adrenal hyperplasia*. *Best Pract Res Clin*
474 *Endocrinol Metab*, 2009. **23**(2): p. 181-92.
- 475 22. Jansen, H.I., et al., *Description and validation of an equilibrium dialysis ID-LC-MS/MS*
476 *candidate reference measurement procedure for free thyroxine in human serum*. *Clin Chem*
477 *Lab Med*, 2023.
- 478 23. McEnroe, R.J., et al., *Evaluation of Linearity of Quantitative Measurement Procedures EP06*.
479 2020, Clinical and Laboratory Standards Institute.
- 480 24. Clarke, W., et al., *Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline*
481 *C62-A Vol. 34*. 2014: Clinical and Laboratory Standards Institute.
- 482 25. McEnroe, R.J., et al., *Evaluation of Precision of Quantitative Measurement Procedures EP05*. 3
483 ed. Vol. 34. 2014: Clinical and Laboratory Standards Institute.
- 484 26. Eyal, O., et al., *Establishing Normal Ranges of Basal and ACTH-Stimulated Serum Free Cortisol*
485 *in Children*. *Horm Res Paediatr*, 2016. **86**(2): p. 94-99.
- 486 27. Rauschecker, M., et al., *Cosyntropin-Stimulated Serum Free Cortisol in Healthy, Adrenally*
487 *Insufficient, and Mildly Cirrhotic Populations*. *J Clin Endocrinol Metab*, 2016. **101**(3): p. 1075-
488 81.
- 489 28. Vogeser, M., J. Briegel, and R. Zachoval, *Dialyzable free cortisol after stimulation with*
490 *Synacthen®*. *Clinical Biochemistry*, 2002. **35**(7): p. 539-543.
- 491 29. Hamrahian, A.H., T.S. Oseni, and B.M. Arafah, *Measurements of serum free cortisol in*
492 *critically ill patients*. *N Engl J Med*, 2004. **350**(16): p. 1629-38.
- 493 30. Waaijers, S., et al., *Measuring steroids in hair opens up possibilities to identify congenital*
494 *adrenal hyperplasia in developing countries*. *Clin Endocrinol (Oxf)*, 2023. **98**(1): p. 41-48.
- 495 31. Kroon, J., A.M. Pereira, and O.C. Meijer, *Glucocorticoid Sexual Dimorphism in Metabolism:*
496 *Dissecting the Role of Sex Hormones*. *Trends Endocrinol Metab*, 2020. **31**(5): p. 357-367.
- 497 32. Murphy, B.E.P., *Corticosteroid-Binding Globulin (Transcortin)*, in *Encyclopedia of Stress*, G.
498 Fink, Editor. 2007, Academic Press. p. 605-613.
- 499 33. Dickinson, P., et al., *Effects of testosterone treatment on plasma proteins and amino acids in*
500 *men*. *J Clin Endocrinol Metab*, 1969. **29**(6): p. 837-41.
- 501 34. Fiet, J., et al., *A Liquid Chromatography/Tandem Mass Spectrometry Profile of 16 Serum*
502 *Steroids, Including 21-Deoxycortisol and 21-Deoxycorticosterone, for Management of*
503 *Congenital Adrenal Hyperplasia*. *J Endocr Soc*, 2017. **1**(3): p. 186-201.
- 504 35. Fiet, J., et al., *Comparison of basal and adrenocorticotropin-stimulated plasma 21-*
505 *deoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal*
506 *hyperplasia*. *J Clin Endocrinol Metab*, 1988. **66**(4): p. 659-67.
- 507 36. Turcu, A.F., et al., *Profiles of 21-Carbon Steroids in 21-hydroxylase Deficiency*. *J Clin*
508 *Endocrinol Metab*, 2015. **100**(6): p. 2283-90.
- 509 37. Engels, M., et al., *Testicular Adrenal Rest Tumors: Current Insights on Prevalence,*
510 *Characteristics, Origin, and Treatment*. *Endocr Rev*, 2019. **40**(4): p. 973-987.
- 511 38. Adriaansen, B.P.H., et al., *46,XX males with congenital adrenal hyperplasia: A clinical and*
512 *biochemical description*. Unpublished data (under review), 2024.
- 513 39. Chistiakov, D.A., et al., *Role of androgens in cardiovascular pathology*. *Vasc Health Risk*
514 *Manag*, 2018. **14**: p. 283-290.

- 515 40. Stoupa, A., et al., *Inadequate cortisol response to the tetracosactide (Synacthen®) test in non-*
516 *classic congenital adrenal hyperplasia: an exception to the rule?* *Horm Res Paediatr*, 2015.
517 **83**(4): p. 262-7.
- 518 41. Burke, C.W., *Biologically active cortisol in plasma of oestrogen-treated and normal subjects.*
519 *Br Med J*, 1969. **2**(5660): p. 798-800.
- 520
- 521

522 **Table and figure legends**

523 **Table 1** Demographics of included patients. Continuous data is given as median (IQR).

524

525 **Table 2** Linearity, Imprecision (within and between day) on low and high level, lower limit of quantification
526 (LLOQ), recovery, and ion suppression for free 21DF and free cortisol measured by LC-MS/MS after dialysis.

527

528 **Figure 1** Total and free cortisol and 21DF concentrations (nmol/L) at T0 in patients with classic congenital
529 adrenal hyperplasia (CAH), non-classic congenital adrenal hyperplasia (NCCAH), adrenal insufficiency but not
530 CAH (AI), and controls. (A) Morning (8.00 – 11.00 AM) concentrations of total cortisol; (B) Morning
531 concentrations of free cortisol; (C) total 21DF concentrations (D) Free 21DF concentrations. n.s. non-significant,
532 * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

533

534 **Figure 2** Increase of total and free cortisol and 21DF concentrations (nmol/L) before (T0) and after (T60)
535 Synacthen® in patients with classic congenital adrenal hyperplasia (CAH), non-classic congenital adrenal
536 hyperplasia (NCCAH), adrenal insufficiency but not CAH (AI), and controls. (A) Change in total cortisol
537 concentrations; (B) Change in free cortisol concentrations; (C) Change in total 21DF concentrations; (D) Change
538 in free 21DF concentrations. * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

539



Table 1 Demographics of included patients. Continuous data is given as median (IQR).

	CAH	NCCAH	AI	Control
Number (n)	29	5	3	11
Age (years)	13.2 (3.3 – 19.6)	8.9 (6.0 – 18.7)	16.1 (11.8 – 17.3)	9.8 (7.9 – 14.7)
Genotype (% 46,XY)	10.3	40.0	33.3	63.6
Sex (% males)	41.4	40.0	33.3	63.6
Diagnosis / Indication for Synacthen® test	CAH (100%)	NCCAH (100%)	X-ALD (33.3%) AD (33.3%) Unknown (33.3%)	Screening X-ALD (18%) Premature pubarche (18%) Screening hypothyroidism (18%) Fatigue (9%) Collapse and hypotension (9%) Screening MEN-1 (9%) Rapid postnatal growth (9%) Once measured low cortisol (9%)



Table 2 Linearity, Imprecision (within and between day) on low and high level, lower limit of quantification (LLOQ), recovery, and ion suppression for free 21DF and free cortisol measured by LC-MS/MS after dialysis.



	<u>Free 21DF</u>	<u>Free Cortisol</u>
Linearity		
<i>Linearity range (nmol/L)</i>	0.13 – 99.2	0.08 – 66.0
<i>Deviation from linearity (%)</i>	1.55	0.96
Imprecision low		
<i>Concentration (nmol/L)</i>	0.36	11.4
<i>Within day (%)</i>	2.8	2.6
<i>Between day (%)</i>	8.5	4.6
Imprecision high		
<i>Concentration (nmol/L)</i>	4.89	104.4
<i>Within day (%)</i>	3.3	2.5
<i>Between day (%)</i>	2.8	4.0
LLOQ (nmol/L)	0.19	<0.32*
Recovery		
<i>Concentration (nmol/L)</i>	29.94	1.496
<i>Average recovery (%)</i>	108	97.3
Ion suppression (%)	<1	<1

*mean CV of 6.1%



■ CAH ■ NCCAHA ■ AI ■ Control





■ CAH ■ NCCAHA ■ AI ■ Control

